Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes. Fielden J, Leblanc P, Parezanovic C, Sridhar VS, et al. Diabet Med 2026 Sep 4:e70463. doi: 10.1111/dme.70463.

Read + Share

Amedeo Smart

Independent Medical Education

Fielden J, Leblanc P, Parezanovic C, Sridhar VS, et al. Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes. Diabet Med 2026 Sep 4:e70463. doi: 10.1111/dme.70463.
PMID: 42698185